Tag: Sickle-Cell Anemia
Gene Therapy Not Cost-Effective for Sickle Cell by Conventional Measures
The inequality aversion parameter would need to be 0.90 for gene therapy to be preferred per distributional cost-effectiveness analysis standards
Study Explores Correlates of Pain Associated With Sickle Cell
Increased pain frequency seen in association with unemployment, female sex, depression
TKA Complications Increased for Sickle Cell Disease Patients
Patients with sickle cell disease have longer length of stay, incur greater health care costs, have increased need for step-down health care facilities
Hydroxyurea Underused in Youth With Sickle Cell
Majority of youth in Michigan and New York with sickle cell anemia did not have filled hydroxyurea prescriptions
Youth With Hematologic, Oncologic Conditions Benefit From Massage
Benefits seen across all patient conditions for pain, stress, and anxiety
ASA: Stem Cell Transplant Improves Vasculopathy in Sickle Cell Patients
No patients without evidence of vasculopathy at transplant developed stenoses or aneurysms after hematopoietic stem cell transplantation
U.S. Maternal Mortality, Morbidity Increased in Sickle Cell Disease
Median of 28.9 percent of the increased risk of deliveries to people with SCD was explained by racial disparities
Transcranial Doppler, Hydroxyurea Use Low for Sickle Cell Anemia
Despite increases in TCD screening and hydroxyurea use from 2014 to 2019, use still remains low for children, teens
Burden of Medical Costs for Sickle Cell Disease Quantified
Over nonelderly lifetime, SCD-attributable costs were estimated at $1.7 million for males; with out-of-pocket costs of $45,091
Systemic Corticosteroids Tied to Vaso-Occlusive Episodes in Sickle Cell
Association seen among children and adults with sickle cell disease; association lower for those exposed to hydroxyurea
